Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Guy Amit, Amit Rosen, Avraham B. Wagshal, Dan Y. Bonneh, Tzvika Liss, Aviva Grosbard, Reuven Ilia, Amos Katz

    Research output: Contribution to journalArticlepeer-review

    11 Scopus citations

    Abstract

    The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.

    Original languageEnglish
    Pages (from-to)1558-1560
    Number of pages3
    JournalAmerican Journal of Cardiology
    Volume93
    Issue number12
    DOIs
    StatePublished - 15 Jun 2004

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation'. Together they form a unique fingerprint.

    Cite this